Nociceptin/orphanin FQ receptors modulate the discriminative stimulus effects of oxycodone in C57BL/6 mice

• Published in: Drug and alcohol dependence 2018-06, Vol.187, p.335-342
• Main Authors: Walentiny, D. Matthew, Wiebelhaus, Jason M., Beardsley, Patrick M.
• Format: Article
• Language: English
• Subjects: Activation; Analgesics; Analgesics, Opioid - pharmacology; Animals; Benzimidazoles - pharmacology; Discrimination; Dosage; Drug abuse; Drug discrimination; Efficacy; Heroin; Hostility; Imidazoles - pharmacology; Ligands; Male; Mice; Mice, Inbred C57BL; Morphine; Morphine - pharmacology; Naloxone; Naloxone - pharmacology; Narcotics; Nociceptin; Nociceptin receptors; Nociceptin/orphanin FQ (NOP) receptor; Operant conditioning; Opioid; Opioid receptors; Opioid-Related Disorders - drug therapy; Opioids; Oxycodone; Oxycodone - pharmacology; Piperidines - pharmacology; Pretreatment; Receptor mechanisms; Receptors; Receptors, Opioid - drug effects; Side effects; Spiro Compounds - pharmacology; Stimulus; Substance abuse; Therapeutic applications
• ISSN: 0376-8716; 1879-0046
• DOI: 10.1016/j.drugalcdep.2018.02.035

•A novel oxycodone discrimination procedure in mice is described.•Naloxone pretreatment blocks oxycodone’s discriminative stimulus effects.•Heroin and morphine fully substitute for oxycodone, but U50488 does not.•Ro64-6198 (Nociceptin/orphanin FQ [NOP] receptor agonist) attenuates oxycodone’s discriminative stimulus.•NOP agonists may dampen subjective effects of prescription opioids. Nociceptin/orphanin FQ (NOP) receptor ligands have shown efficacy as putative analgesics and can modulate the abuse-related effects of opioids, suggesting therapeutic applications. The discriminative stimulus effects of a drug are related to their subjective effects, a predictor of abuse potential. To determine whether activation of NOP receptors could alter the subjective effects of an abused opioid analgesic, a novel oxycodone discrimination was established in mice, characterized with positive and negative controls, and its expression evaluated with a NOP receptor agonist. Adult male C57BL/6 mice were trained to discriminate 1.3 mg/kg oxycodone from vehicle in a two-lever operant procedure. The discrimination was characterized with naloxone challenge, and generalization tests with the μ-opioid receptor agonists, heroin and morphine, and the κ-opioid receptor selective agonist, U50488. Subsequently, effects of the NOP agonist Ro64-6198 were evaluated with and without oxycodone. Oxycodone generalization occurred in a dose-dependent manner and was reversed by naloxone pretreatment. Heroin and morphine, but not U50488, substituted for oxycodone. Co-treatment of 1 mg/kg Ro64-6198 with the oxycodone training dose reduced % oxycodone lever responding (%OLR) and restored response rates to vehicle control levels. J-113397, a NOP antagonist, reversed these effects. Co-administration of 1 mg/kg Ro64-6198 with a range of oxycodone doses resulted in rightward dose-effect curve shifts in %OLR and response rates compared to oxycodone alone. These results provide additional evidence that NOP receptor activation can modulate the subjective effects of opioid analgesics and represent the first characterization of oxycodone’s discriminative stimulus effects in mice.